A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped See termination reason in detailed description.

Conditions

Type 2 Diabetic Nephropathy

Interventions

DRUG: PF-03882845
DRUG: PF-03882845
DRUG: PF-03882845
DRUG: Spironolactone
OTHER: placebo

Sponsor

Pfizer